111511-90-1

Basic information

• Product Name: dihydro-2H-pyran-4,4(3H)-dicarbonitrile
• Synonyms: dihydro-2H-pyran-4,4(3H)-dicarbonitrile;Tetrahydropyran-4,4-dicarbonitrile;Tetrahydro-4H-pyran-4,4-dicarbonitrile;oxane-4,4-dicarbonitrile
• CAS NO: 111511-90-1
• Molecular Formula: C₇H₈N₂O
• Molecular Weight: 136.15122
• Mol File: 111511-90-1.mol

Chemical Properties

• Melting Point: 113-114 °C(Solv: ethanol (64-17-5))
• Boiling Point: 335.5±42.0 °C(Predicted)
• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• CAS DataBase Reference: dihydro-2H-pyran-4,4(3H)-dicarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: dihydro-2H-pyran-4,4(3H)-dicarbonitrile(111511-90-1)
• EPA Substance Registry System: dihydro-2H-pyran-4,4(3H)-dicarbonitrile(111511-90-1)

Safety Data

• Hazardous Substances Data: 111511-90-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Dihydro-2H-pyran-4,4(3H)-dicarbonitrile is used as a key intermediate in the synthesis of potent anti-HIV agents. Its unique structural features allow for the development of new drugs that can effectively combat the Human Immunodeficiency Virus (HIV).
Used in Medicinal Chemistry:
In the field of medicinal chemistry, dihydro-2H-pyran-4,4(3H)-dicarbonitrile is utilized in the preparation of novel, neutral 5-hydroxytryptamine 6 receptor (5-HT6R) antagonists. These antagonists possess unique structural facilities that can potentially be used for the treatment of various neurological and psychiatric disorders, such as Alzheimer's disease, schizophrenia, and depression.
Used in Chemical Synthesis:
Dihydro-2H-pyran-4,4(3H)-dicarbonitrile is also employed as a versatile building block in the synthesis of various organic compounds. Its reactivity and structural properties make it a valuable component in the development of new molecules with potential applications in different industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 111-44-4 3-oxa-1,5-dichloropentane 
• 109-77-3 malononitrile 
• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 

Downstream Products

• 111511-91-2 tetrahydro-4H-pyran-4,4-dimethanamine dihydrochloride 
• 5337-04-2 tetrahydro-4H-pyran-4,4-dicarboxylic acid 
• 1263374-32-8 4-(aminomethyl)tetrahydro-2H-pyran-4-carbonitrile 
• 1337565-39-5 N-[(8-oxa-2,3-diaza-spiro[4.5]dec-3-en-2-yl)-methylsulfanyl-methylidene]-3-chlorobenzenesulfonamide 
• 1015169-93-3 N-[ethylamino-(8-oxa-2,3-diaza-spiro[4.5]dec-3-en-2-yl)methylidene]-3-chlorobenzenesulfonamide 
• 1263374-47-5 4-((6-(benzyloxy)-3-fluoropyridin-2-yl-amino)methyl)tetrahydro-2H-pyran-4-carbonitrile 
• 1403578-85-7 3-(4-bromo-2-fluorophenyl)-9-oxa-2,4-diazaspiro[5.5]undec-2-ene 
• 104-85-8 para-methylbenzonitrile 
• 100-47-0 benzonitrile 

Relevant articles and documents

Water-soluble third generation antitumor platinum complexes, [2,2-bis(aminomethyl)-1,3-propanediol-N,N'][1,1-cyclobutanedicarboxylato(2- )-O,O']platinum(II) and [1,1-cyclobutanedicarboxylato(2-)-O,O'][tetrahydro-4H-pyran-4,4- dimethanamine-N,N']platinum(II)

The synthesis, stability, and antitumor activity of a series of water-soluble third generation platinum(II) complexes have been described. Among these complexes, [2,2-bis(aminomethyl)-1,3-propanediol-N,N'][1,1-cyclobutanedicarboxylato(2- )-O,O']platinum(II) and [1,1-cyclobutanedicarboxylato(2-)-O,O'](tetrahydro-4H-pyran-4,4- dimethanamine-N,N')platinum(II) have shown the greatest promise for further investigation and are currently under clinical evaluation.

CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF

The present disclosure provides CDK9 inhibitors. Also provided are methods of treating a disease or a disorder comprising administering to a subject in need of treatment one of the CDK9 inhibitors disclosed herein. In some embodiments, the disease or diso

Structure-activity relationship study of pyrimido[1,2-c][1,3]benzothiazin- 6-imine derivatives for potent anti-HIV agents

3,4-Dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (PD 404182) is an antiretroviral agent with submicromolar inhibitory activity against human immunodeficiency virus-1 (HIV-1) and HIV-2 infection. In the current study, the structure-activity relationships of accessory groups at the 3- and 9-positions of pyrimido[1,2-c][1,3]benzothiazin-6-imine were investigated for the development of more potent anti-HIV agents. Several different derivatives containing a 9-aryl group were designed and synthesized using Suzuki-Miyaura cross-coupling and Ullmann coupling reactions. Modification of the m-methoxyphenyl or benzo[d][1,3]dioxol-5-yl group resulted in improved anti-HIV activity. In addition, the 2,4-diazaspiro[5.5]undec-2-ene-fused benzo[e][1,3]thiazine derivatives were designed and tested for their anti-HIV activities. The most potent 9-(benzo[d][1,3]dioxol-5-yl) derivative was two-threefold more effective against several strains of HIV-1 and HIV-2 than the parent compound, PD 404182.

PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds

3-(AMINOARYL)-PYRIDINE COMPOUNDS

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.

N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES

The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.

PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a pyrimidine compound of formula (I): wherein one of X and Y but not both is N, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tantomers, diastereomers, deuterated versions, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds

HETEROARYL COMPOUNDS AS KINASE INHIBITORS

The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor